Tearsheet

CERo Therapeutics (CERO)

Market Price (10/31/2025): $0.125 | Market Cap: $61,010
Sector: Health Care | Industry: Biotechnology

CERo Therapeutics (CERO)

Market Price (10/31/2025): $0.125
Market Cap: $61,010
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -5430%	Weak multi-year price returns 2Y Excs Rtn is -165%, 3Y Excs Rtn is -177%	Penny stock Mkt Price is 0.1
1			Very low revenue Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
2			Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -20 Mil
3			Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -35245%
4			High stock price volatility Vol 12M is 1794%
5			Significant short interest Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 40%

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -5430%
1	Weak multi-year price returns 2Y Excs Rtn is -165%, 3Y Excs Rtn is -177%
2	Penny stock Mkt Price is 0.1
3	Very low revenue Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
4	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -20 Mil
5	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -35245%
6	High stock price volatility Vol 12M is 1794%
7	Significant short interest Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 40%

Market Valuation & Key Metrics

Valuation
Key Metrics

	10/31/25	2024	2023	2022	2021
Share Price CYE	$0.12	$2,400.00	$440,000.00	$410,812.00	$396,400.00
Market Cap CYE ($ Mil)	0.1	59.6	2,624.2	1,861.4	193,473.3
Total Debt ($ Mil)	1.2	2.9	3.0	3.6	0.0
Total Cash ($ Mil)	3.8	1.6	6.8	19.2	0.0
Enterprise Value ($ Mil)	-2.6	62.5	2,627.2	1,865.0	193,473.3
Valuation Ratios
P/S TTM	0.0	0.0	0.0	0.0	0.0
P/EBIT TTM	0.0	-0.1	-8.3	-8.0	0.0
P/E TTM	0.0	-0.1	-8.4	-8.8	0.0
Sector Ratios
P/S TTM (Sector)	4.1	3.5	4.0	4.5	7.3
P/EBIT TTM (Sector)	-1.6	-1.3	-1.4	-1.3	-2.7
P/E TTM (Sector)	-2.0	-1.5	-1.5	-1.3	-2.8

	10/31/25	2024	2023	2022
Share Price CYE	$0.12	$2,400.00	$440,000.00	$410,812.00
Market Cap CYE ($ Mil)	0.1	59.6	2,624.2	1,861.4
Total Debt ($ Mil)	1.2	2.9	3.0	3.6
Total Cash ($ Mil)	3.8	1.6	6.8	19.2
Enterprise Value ($ Mil)	-2.6	62.5	2,627.2	1,865.0
Valuation Ratios
P/S TTM	0.0	0.0	0.0	0.0
P/EBIT TTM	0.0	-0.1	-8.3	-8.0
P/E TTM	0.0	-0.1	-8.4	-8.8
Sector Ratios
P/S TTM (Sector)	4.1	3.5	4.0	4.5
P/EBIT TTM (Sector)	-1.6	-1.3	-1.4	-1.3
P/E TTM (Sector)	-2.0	-1.5	-1.5	-1.3

null

CERO Stock

Return (1M):

Factor Drivers of Stock Movement

The -98.8% change in CERO stock from 7/31/2025 to 10/30/2025 was primarily driven by a -184.8% change in the company's Shares Outstanding (Mil).

	7312025	10302025	Change
Stock Price ($)	7.76	0.10	-98.77%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	0.00	0.00	�
P/S Multiple	∞	∞	�
Shares Outstanding (Mil)	0.17	0.49	-184.79%
Cumulative Contribution			�

LTM = Last Twelve Months as of date shown

The -100.0% change in CERO stock from 5/1/2025 to 10/30/2025 was primarily driven by a -8083.7% change in the company's Shares Outstanding (Mil).

	5012025	10302025	Change
Stock Price ($)	356.72	0.10	-99.97%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	0.00	0.00	�
P/S Multiple	∞	∞	�
Shares Outstanding (Mil)	0.01	0.49	-8083.70%
Cumulative Contribution			�

LTM = Last Twelve Months as of date shown

The -100.0% change in CERO stock from 10/30/2024 to 10/30/2025 was primarily driven by a -10671.9% change in the company's Shares Outstanding (Mil).

	10302024	10302025	Change
Stock Price ($)	3260.00	0.10	-100.00%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	�	0.00	�
P/S Multiple	�	∞	�
Shares Outstanding (Mil)	0.00	0.49	-10671.93%
Cumulative Contribution			�

LTM = Last Twelve Months as of date shown

null

null

Return vs. Risk

Price Returns Compared

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
CERO Return	-	-	4%	7%	-99%	-100%	-100%
Peers Return	-15%	-9%	-6%	-3%	-3%	-16%	-43%
S&P 500 Return	16%	27%	-19%	24%	23%	16%	110%
Monthly Win Rates [3]
CERO Win Rate	-	0%	92%	75%	25%	11%
Peers Win Rate	18%	15%	23%	31%	22%	51%
S&P 500 Win Rate	58%	75%	42%	67%	75%	67%
Max Drawdowns [4]
CERO Max Drawdown	-	-	0%	0%	-100%	-100%
Peers Max Drawdown	-20%	-13%	-14%	-15%	-30%	-27%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: VRTX, APM, BBOT, GDTC, HIND.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 10/30/2025 (YTD)

How Low Can It Go

Unique Key	Event	CERO	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-2.6%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	2.7%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	209 days	464 days

Compare to VRTX, APM, BBOT, GDTC, HIND

In The Past

CERo Therapeutics's stock fell -2.6% during the 2022 Inflation Shock from a high on 4/27/2023. A -2.6% loss requires a 2.7% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About CERo Therapeutics (CERO)

Business Description

Phoenix Biotech Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It engages in identifying and acquiring a business that focuses on the healthcare or healthcare related industries in the United States and Europe. The company was incorporated in 2021 and is based in Oakland, California.

Better Bets than CERo Therapeutics (CERO)

	CERO	Better Performance than CERO
Metric	Value	Industry (Biotechnology)
Total Yield	-35240.1%	ABBV (3.7%), AMGN (7.4%), GILD (7.0%), VRTX (3.4%), REGN (7.2%)

	CERO	Better Performance than CERO
Metric	Value	Sector (Health Care)
Total Yield	-35240.1%	LLY (2.5%), JNJ (8.2%), ABBV (3.7%), UNH (8.1%), ABT (8.3%)

	CERO	Better Performance than CERO
Metric	Value	All Other Sectors
Total Yield	-35240.1%	NVDA (1.8%), AAPL (2.8%), MSFT (3.3%), GOOGL (3.9%), AMZN (3.0%)

		Best Bets In Health Care Sector
	CERO	RPRX	HALO	CPRX	BMY	LNTH	PBH	BIIB	PFE	EW	ILMN
What You Pay
P/E	-0.0	15.3	14.1	12.3	15.4	14.0	14.0	13.6	12.8	11.8	12.4
P/EBIT	-0.0	8.1	11.0	10.5	9.3	9.6	9.0	10.1	10.3	29.2	10.3
What You Get
Rev Chg Q	�	7.7%	40.8%	19.4%	2.8%	-4.1%	-6.6%	2.8%	10.3%	11.9%	-4.8%
Rev Chg LTM	�	3.0%	35.0%	28.5%	1.3%	5.7%	0.6%	4.8%	13.5%	9.1%	-3.3%
Rev Chg 3Y Avg	�	0.8%	35.5%	49.9%	1.0%	34.3%	0.8%	-0.9%	-12.4%	3.0%	-3.0%
FCF/Rev 3Y Avg	�	113.4%	43.4%	38.9%	29.0%	26.1%	21.6%	17.0%	13.8%	11.9%	9.0%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Trade Ideas

Select past ideas related to CERO. For more, see Trefis Trade Ideas.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy	09302025	ADMA	ADMA Biologics	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	5.9%	5.9%	-4.6%
REGN_9302025_Dip_Buyer_ValueBuy	09302025	REGN	Regeneron Pharmaceuticals	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	16.1%	16.1%	-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	09262025	HAE	Haemonetics	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	2.6%	2.6%	-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper	09192025	WAT	Waters	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	14.2%	14.2%	-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper	09052025	ISRG	Intuitive Surgical	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	15.2%	15.2%	-8.0%

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy	09302025	ADMA	ADMA Biologics	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	5.9%	5.9%	-4.6%
REGN_9302025_Dip_Buyer_ValueBuy	09302025	REGN	Regeneron Pharmaceuticals	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	16.1%	16.1%	-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	09262025	HAE	Haemonetics	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	2.6%	2.6%	-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper	09192025	WAT	Waters	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	14.2%	14.2%	-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper	09052025	ISRG	Intuitive Surgical	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	15.2%	15.2%	-8.0%

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	GH	Guardant Health	27.9%	202.5%
2	GCI	Gannett	27.7%	3.8%
3	FORM	FormFactor	24.2%	34.7%
4	VIAV	Viavi Solutions	22.3%	69.3%
5	GSAT	Globalstar	22.2%	63.5%
6	MTSR	Metsera	22.1%	63729900.0%
7	PRM	Perimeter Solutions	21.1%	102.3%
8	CHRW	C.H. Robinson Worldwide	19.7%	52.6%
9	INSM	Insmed	16.3%	181.3%
10	CAH	Cardinal Health	15.4%	62.8%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	FMC	FMC	-46.5%	-66.6%
2	APLS	Apellis Pharmaceuticals	-31.0%	-35.0%
3	THRY	Thryv	-30.2%	-44.8%
4	SFM	Sprouts Farmers Market	-26.1%	-39.2%
5	IART	Integra Lifesciences	-23.5%	-47.9%
6	ITRI	Itron	-21.1%	0.4%
7	WOLF	Wolfspeed	-18.2%
8	CMG	Chipotle Mexican Grill	-18.2%	-46.1%
9	CI	Cigna	-17.4%	-9.2%
10	EME	EMCOR	-16.6%	43.0%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	INBX	Inhibrx Biosciences	176.8%	409.8%
2	PUMP	ProPetro	71.2%	16.2%
3	RNA	Avidity Biosciences	43.5%	139.6%
4	DYN	Dyne Therapeutics	42.8%	-0.0%
5	GCI	Gannett	39.3%	3.8%
6	FORM	FormFactor	38.3%	34.7%
7	MBX	MBX Biosciences	35.1%	18.2%
8	BBNX	Beta Bionics	33.8%
9	GH	Guardant Health	33.3%	202.5%
10	LUMN	Lumen Technologies	32.7%	94.7%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	PMI	Picard Medical	-75.2%	5106.3%
2	LRN	Stride	-56.1%	-35.8%
3	NTLA	Intellia Therapeutics	-52.6%	5.2%
4	FMC	FMC	-48.7%	-66.6%
5	FI	Fiserv	-47.4%	-68.3%
6	VRNS	Varonis Systems	-43.8%	-21.2%
7	THRY	Thryv	-33.4%	-44.8%
8	NFE	New Fortress Energy	-30.5%	-91.9%
9	AKBA	Akebia Therapeutics	-29.5%	10.5%
10	UAMY	United States Antimony	-28.9%	371.2%

1 Month Top Gainers

#	Ticker	Company	1M Rtn	YTD Rtn
1	PRAX	Praxis Precision Medicines	279.1%	161.2%
2	INBX	Inhibrx Biosciences	131.0%	409.8%
3	PUMP	ProPetro	99.6%	16.2%
4	DYN	Dyne Therapeutics	88.4%	-0.0%
5	VICR	Vicor	85.4%	89.2%
6	CELC	Celcuity	74.6%	503.2%
7	GLUE	Monte Rosa Therapeutics	73.5%	87.5%
8	NVTS	Navitas Semiconductor	72.1%	251.8%
9	LUMN	Lumen Technologies	70.3%	94.7%
10	BALY	Ballys	63.4%	4.1%

1 Month Top Losers

#	Ticker	Company	1M Rtn	YTD Rtn
1	PMI	Picard Medical	-62.9%	5106.3%
2	LRN	Stride	-53.8%	-35.8%
3	FMC	FMC	-51.0%	-66.6%
4	FI	Fiserv	-48.3%	-68.3%
5	NFE	New Fortress Energy	-43.6%	-91.9%
6	VG	Venture Global	-41.7%
7	OGN	Organon	-40.2%	-55.0%
8	VRNS	Varonis Systems	-39.5%	-21.2%
9	ITGR	Integer	-38.5%	-52.2%
10	LENZ	LENZ Therapeutics	-37.9%	5.5%

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	GH	Guardant Health	27.9%	202.5%
2	GCI	Gannett	27.7%	3.8%
3	FORM	FormFactor	24.2%	34.7%
4	VIAV	Viavi Solutions	22.3%	69.3%
5	GSAT	Globalstar	22.2%	63.5%
6	MTSR	Metsera	22.1%	63729900.0%
7	PRM	Perimeter Solutions	21.1%	102.3%
8	CHRW	C.H. Robinson Worldwide	19.7%	52.6%
9	INSM	Insmed	16.3%	181.3%
10	CAH	Cardinal Health	15.4%	62.8%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	FMC	FMC	-46.5%	-66.6%
2	APLS	Apellis Pharmaceuticals	-31.0%	-35.0%
3	THRY	Thryv	-30.2%	-44.8%
4	SFM	Sprouts Farmers Market	-26.1%	-39.2%
5	IART	Integra Lifesciences	-23.5%	-47.9%
6	ITRI	Itron	-21.1%	0.4%
7	WOLF	Wolfspeed	-18.2%
8	CMG	Chipotle Mexican Grill	-18.2%	-46.1%
9	CI	Cigna	-17.4%	-9.2%
10	EME	EMCOR	-16.6%	43.0%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	INBX	Inhibrx Biosciences	176.8%	409.8%
2	PUMP	ProPetro	71.2%	16.2%
3	RNA	Avidity Biosciences	43.5%	139.6%
4	DYN	Dyne Therapeutics	42.8%	-0.0%
5	GCI	Gannett	39.3%	3.8%
6	FORM	FormFactor	38.3%	34.7%
7	MBX	MBX Biosciences	35.1%	18.2%
8	BBNX	Beta Bionics	33.8%
9	GH	Guardant Health	33.3%	202.5%
10	LUMN	Lumen Technologies	32.7%	94.7%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	PMI	Picard Medical	-75.2%	5106.3%
2	LRN	Stride	-56.1%	-35.8%
3	NTLA	Intellia Therapeutics	-52.6%	5.2%
4	FMC	FMC	-48.7%	-66.6%
5	FI	Fiserv	-47.4%	-68.3%
6	VRNS	Varonis Systems	-43.8%	-21.2%
7	THRY	Thryv	-33.4%	-44.8%
8	NFE	New Fortress Energy	-30.5%	-91.9%
9	AKBA	Akebia Therapeutics	-29.5%	10.5%
10	UAMY	United States Antimony	-28.9%	371.2%

Peer Comparisons for CERo Therapeutics

Financials

	CERO	VRTX	APM	BBOT	GDTC	HIND	Median
Name	CERo The.	Vertex P.	Aptorum	BridgeBi.	CytoMed .	Vyome
Mkt Price	0.10	419.89	1.47	12.00	2.15	5.58	3.87
Mkt Cap	0.0	107.8	-	-	-	-	53.9
Rev LTM	0	11,419	-	0	-	-	0
Op Inc LTM	-20	-199	-	-93	-	-	-93
FCF LTM	-	3,500	-	-60	-	-	1,720
FCF 3Y Avg	-	1,984	-	-	-	-	1,984
CFO LTM	-	3,846	-	-60	-	-	1,893
CFO 3Y Avg	-	2,324	-	-	-	-	2,324

Growth & Margins

	CERO	VRTX	APM	BBOT	GDTC	HIND	Median
Name	CERo The.	Vertex P.	Aptorum	BridgeBi.	CytoMed .	Vyome
Rev Chg LTM	-	10.5%	-	-	-	-	10.5%
Rev Chg 3Y Avg	-	11.0%	-	-	-	-	11.0%
Rev Chg Q	-	12.1%	-	-	-	-	12.1%
QoQ Delta Rev Chg LTM	-	2.9%	-	-	-	-	2.9%
Op Mgn LTM	-	-1.7%	-	-	-	-	-1.7%
Op Mgn 3Y Avg	-	26.5%	-	-	-	-	26.5%
QoQ Delta Op Mgn LTM	-	2.0%	-	-	-	-	2.0%
CFO/Rev LTM	-	33.7%	-	-	-	-	33.7%
CFO/Rev 3Y Avg	-	22.5%	-	-	-	-	22.5%
FCF/Rev LTM	-	30.6%	-	-	-	-	30.6%
FCF/Rev 3Y Avg	-	19.2%	-	-	-	-	19.2%

Valuation

	CERO	VRTX	APM	BBOT	GDTC	HIND	Median
Name	CERo The.	Vertex P.	Aptorum	BridgeBi.	CytoMed .	Vyome
Mkt Cap	0.0	107.8	-	-	-	-	53.9
P/S	-	9.4	-	-	-	-	9.4
P/EBIT	-0.0	24.5	-	-	-	-	12.3
P/E	-0.0	29.6	-	-	-	-	14.8
P/CFO	-	28.0	-	-	-	-	28.0
Total Yield	-35,240.1%	3.4%	-	-	-	-	-17,618.4%
Dividend Yield	0.0%	0.0%	-	-	-	-	0.0%
FCF Yield 3Y Avg	-	2.1%	-	-	-	-	2.1%
D/E	23.6	0.0	-	-	-	-	11.8
Net D/E	-54.3	-0.0	-	-	-	-	-27.2

Returns

	CERO	VRTX	APM	BBOT	GDTC	HIND	Median
Name	CERo The.	Vertex P.	Aptorum	BridgeBi.	CytoMed .	Vyome
1M Rtn	-98.1%	7.2%	-27.2%	3.6%	8.0%	7.7%	5.4%
3M Rtn	-98.8%	-8.1%	-5.2%	-	14.4%	-	-6.6%
6M Rtn	-100.0%	-15.8%	59.8%	-	-6.5%	-	-11.2%
12M Rtn	-100.0%	-11.6%	5.0%	-	-3.4%	-	-7.5%
3Y Rtn	-100.0%	34.6%	-76.8%	-	-	-	-76.8%
1M Excs Rtn	-99.9%	2.2%	-34.2%	-1.9%	5.3%	-0.2%	-1.1%
3M Excs Rtn	-108.1%	-18.5%	-2.1%	-	8.1%	-	-10.3%
6M Excs Rtn	-121.7%	-37.6%	38.0%	-	-28.3%	-	-32.9%
12M Excs Rtn	-117.1%	-29.0%	-17.8%	-	-33.2%	-	-31.1%
3Y Excs Rtn	-176.8%	-41.0%	-151.9%	-	-	-	-151.9%

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2023	2022	2021
Period End	6/30/2025	12/31/2023	12/31/2022	12/31/2021
Filing Date	8/22/2025	4/15/2025	8/14/2023	8/14/2023
Key Financials
Total Revenue	0	0	0	0
EBITDA	-20	-7	-11	-11
Operating Income	-20	-8	-12	-12
Net Income	-17	-7	-12	-11
EPS	-575.83	-1416.55	-2610.71	-2345.98
Growth Rates
Total Revenue Growth	-	-	-	-
EBITDA Growth	-205.9%	39.8%	-0.2%	-
Operating Income Growth	-167.5%	35.9%	-3.1%	-
Net Income Growth	-140.7%	38.4%	-11.3%	-
Margins
EBITDA Margin	-	-	-	-
Operating Income Margin	-	-	-	-
Net Income Margin	-	-	-	-
Cash & Debt
Total Cash	4	2	7	19
Total Debt	1	3	3	4
Net Debt / (Cash)	-3	1	-4	-16
Cash Flows
Net Cash from Operations	-	-6	-12	-10
Free Cash from Operations	-	-6	-12	-11
Returns to Shareholders
Dividends	0	-0	-0	-0
Share Repurchases	0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q2	2025Q1	2024Q3	2024Q2	2023Q4	2023Q3	2023Q2	2023Q1	2022Q1
Period End	6/30/2025	3/31/2025	9/30/2024	6/30/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	3/31/2022
Filing Date	8/22/2025	5/15/2025	11/19/2024	8/14/2024	4/15/2025	11/20/2024	8/14/2024	8/14/2023	8/14/2023
Key Financials Quarterly
Total Revenue	0	0	0	0	0	0	0	0	0
Ebitda	-5	-5	-4	-5	-1	-1	-2	-2	-3
Operating Income	-5	-5	-4	-5	-1	-2	-2	-2	-4
Net Income	-5	-5	-4	-2	-1	-1	-2	-2	-4
EPS	-61.71	-31.80	-180.00	-302.32	-245.86	-262.21	-460.00	-538.14	-775.82
Key Financials TTM
Total Revenue TTM	0	0	0	0	0	0	-	-	-
Ebitda TTM	-20	-15	-12	-9	-6	-9	-	-	-
Operating Income TTM	-20	-16	-12	-10	-8	-10	-	-	-
Net Income TTM	-17	-13	-9	-7	-7	-9	-	-	-
Growth Rates Quarterly
Total Revenue Growth	-	-	-	-	-	-	-	-	-
EBITDA Growth	-517.3%	-285.7%	-106.1%	-137.8%	74.5%	-	-	-	-
Operating Income Growth	-384.4%	-232.6%	-82.4%	-111.1%	68.3%	-	-	-	-
Net Income Growth	-328.2%	-278.4%	-102.1%	-0.4%	64.0%	-	-	-	-
Margins Quarterly
EBITDA Margin	-	-	-	-	-	-	-	-	-
Operating Income Margin	-	-	-	-	-	-	-	-	-
Net Income Margin	-	-	-	-	-	-	-	-	-
Cash & Debt
Total Cash	4	5	3	4	2	-	-	5	-
Total Debt	1	1	2	2	3	0	0	3	0
Net Debt / (Cash)	-3	-4	-2	-1	1	-	-	-3	-
Cash Flows Quarterly
FCF from Operations	-5	-4	-	-	-1	-1	-2	-1	-4
Cash Flows TTM
FCF from Operations TTM	-	-	-	-	-6	-9	-	-	-
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-28.2%	-28.4%	-26.6%	-32.5%	-188.8%	-	-	-	-
Return on Invested Capital (ROIC) TTM
ROIC TTM	-26.0%	-22.0%	-18.4%	-16.1%	-316.1%	-	-	-	-

Price Behavior

Price Behavior

Market Price	$0.10
Market Cap ($ Bil)	0.0
First Trading Date	11/30/2021
Distance from 52W High	-100.0%
	50 Days	200 Days
DMA Price	$4.84	$1,908.28
DMA Trend	down	down
Distance from DMA	-98.0%	-100.0%
	3M	1YR
Volatility	215.9%	1,804.9%
Downside Capture	2859.68	261.12
Upside Capture	-132.82	-784.16
Correlation (SPY)	31.5%	-5.5%

CERO Betas & Captures as of 9/30/2025

	1M	2M	3M	6M	1Y	3Y
Beta	2.53	1.08	1.29	-8.00	-5.41	-2.45
Up Beta	11.30	2.29	2.65	2.08	1.81	1.41
Down Beta	0.11	1.95	1.53	-9.15	-6.15	-3.99
Up Capture	-292%	-128%	-118%	-127%	-58%	-5%
Bmk +ve Days	13	23	35	74	144	420
Stock +ve Days	7	14	22	49	93	223
Down Capture	678%	278%	329%	-2125%	-669%	-7%
Bmk -ve Days	8	19	29	52	107	330
Stock -ve Days	14	27	40	75	152	316

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date	10152025
Short Interest: Shares Quantity	192,892
Short Interest: % Change Since 9302025	167.2%
Average Daily Volume	392,912
Days-to-Cover Short Interest	1
Basic Shares Quantity	488,076
Short % of Basic Shares	39.5%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
6302025	8222025	10-Q 6/30/2025
3312025	5152025	10-Q 3/31/2025
9302024	11192024	10-Q 9/30/2024
6302024	8142024	10-Q 6/30/2024
12312023	4152025	10-K 12/31/2023
9302023	11202024	10-Q/A 9/30/2023
12312022	8142023	S-4/A 12/31/2022

Insider Activity

Expand for More

	Owner	Filing Date	Action	Price	Shares	Transacted Value	Value of Held Shares	Form
0	YK Bioventures Opportunities GP I, LLC	12132024	Sell	0.08	1,343,801	107,504	1,409,489	Form
1	YK Bioventures Opportunities GP I, LLC	12102024	Sell	0.12	1,236,874	148,425	2,566,069	Form
2	SLOAN STUART M	11202024	Sell	0.10	532,486	55,538	2,197,388	Form
3	YK Bioventures Opportunities GP I, LLC	11142024	Sell	0.10	3,250,000	325,000	2,262,078	Form

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Biotechnology Resources

Fierce Biotech

Nature Biotechnology

Genetic Engineering & Biotechnology News

Biotechnology Innovation Organization

BioWorld

BioTechniques

HBS Biotechnology Publications

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

CERo Therapeutics (CERO)

Market Price (10/31/2025): $0.125 | Market Cap: $61,010Sector: Health Care | Industry: Biotechnology

CERo Therapeutics (CERO)

Market Price (10/31/2025): $0.125Market Cap: $61,010Sector: Health CareIndustry: Biotechnology

Market Valuation & Key Metrics

CERO Stock

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About CERo Therapeutics (CERO)

Interactive Breakdown

Better Bets than CERo Therapeutics (CERO)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

1 Month Top Gainers

1 Month Top Losers

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for CERo Therapeutics

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

Financials

Segment Financials

Price Behavior

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

Industry Resources

External Quote Links

Market Price (10/31/2025): $0.125 | Market Cap: $61,010
Sector: Health Care | Industry: Biotechnology

Market Price (10/31/2025): $0.125
Market Cap: $61,010
Sector: Health Care
Industry: Biotechnology